Nyxoah (NYXH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nyxoah (NYXH) has a cash flow conversion efficiency ratio of -0.402x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-20.48 Million ≈ $-23.95 Million USD) by net assets (€50.95 Million ≈ $59.57 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Nyxoah worth for the company's overall valuation and market capitalisation.
Nyxoah - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nyxoah's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nyxoah Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nyxoah ranked by their cash flow conversion efficiency. See Nyxoah cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gold Terra Resource Corp
V:YGT
|
-0.011x |
|
Namib Minerals Ordinary Shares
NASDAQ:NAMM
|
-0.351x |
|
Rorze Systems Corporation
KQ:071280
|
0.008x |
|
Harboes Bryggeri A/S
CO:HARB-B
|
0.029x |
|
Abionyx Pharma SA
PA:ABNX
|
-0.314x |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
-0.023x |
|
Maan Aluminium Limited
NSE:MAANALU
|
0.076x |
|
SLP Resources Bhd
KLSE:7248
|
0.017x |
Annual Cash Flow Conversion Efficiency for Nyxoah (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nyxoah from 2017 to 2024. View NYXH share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €113.25 Million ≈ $132.41 Million |
€-49.23 Million ≈ $-57.55 Million |
-0.435x | +4.85% |
| 2023-12-31 | €98.02 Million ≈ $114.60 Million |
€-44.78 Million ≈ $-52.35 Million |
-0.457x | -91.15% |
| 2022-12-31 | €120.32 Million ≈ $140.67 Million |
€-28.76 Million ≈ $-33.62 Million |
-0.239x | -40.19% |
| 2021-12-31 | €148.62 Million ≈ $173.75 Million |
€-25.34 Million ≈ $-29.62 Million |
-0.170x | -141.38% |
| 2020-12-31 | €97.19 Million ≈ $113.63 Million |
€-6.86 Million ≈ $-8.02 Million |
-0.071x | +95.58% |
| 2019-12-31 | €3.71 Million ≈ $4.34 Million |
€-5.93 Million ≈ $-6.94 Million |
-1.598x | -105.20% |
| 2018-12-31 | €10.45 Million ≈ $12.22 Million |
€-8.14 Million ≈ $-9.52 Million |
-0.779x | +57.47% |
| 2017-12-31 | €4.53 Million ≈ $5.29 Million |
€-8.29 Million ≈ $-9.69 Million |
-1.831x | -- |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more